“Important issues related to progress of vaccine development, regulatory approvals and procurement were discussed,” the PM tweeted.
Reviewed various issues like prioritisation of population groups, reaching out to HCWs, cold-chain Infrastructure a… https://t.co/O4Kd6XAXyl
— Narendra Modi (@narendramodi) 1605887514000
The PM reviewed the aspects of emergency use authorisation and manufacture and procurement of medicine. As the results of Phase 3 trials arrive, regulators will speedily examine these for according authorisation for use. Adar Poonawala of Serum Institute, which is manufacturing the vaccine in India, has indicated that it can approach the Indian regulator soon after the UK partner reveals the phase 3 trial results. This means the first shots may be available for priority health worker recipients in India by January.
A press release said the vaccine supply chain was being enhanced and non-vaccine supplies were being escalated. Medical and nursing students and faculty will be involved in training and implementation of the programme.The government has provided aid of Rs 900 crore to support research and development of vaccines.